Sports and Marfan Syndrome

REFERENCES

• Demak R: Marfan syndrome: a silent killer. Sports Illustrated 1986;64:30–35
   Google Scholar
• Dietz HC, Cutting GR, Pyeritz RE, et al: Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature 1991;352(6333):337–339
   PubMed Web of Science ®Google Scholar
• Pyeritz RE: The Marfan syndrome. Annu Rev Med 2000;51: 481–510
   PubMed Web of Science ®Google Scholar
• Pfister GC, Puffer JC, Maron BJ: Preparticipaion cardiovascular screening for US collegiate student-athletes. JAMA 2000;283(12): 1597–1599
   PubMedGoogle Scholar
• Kinoshita N, Mimura J, Obayashi C, et al: Aortic root dilatation among young competitive athletes: echocardiographic screening of 1929 athletes between 15 and 34 years of age. Am Heart J 2000;139(4):723–728
   PubMed Web of Science ®Google Scholar
• Murdoch JL, Walker BA, Halpern BL, et al: Life expectancy and causes of death in the Marfan syndrome. N Engl J Med 1972;286(15):804–808
   PubMed Web of Science ®Google Scholar
• Silverman DI, Burton KJ, Gray J, et al: Life expectancy in the Marfan syndrome. Am J Cardiol 1995;75(2):157–160
   PubMed Web of Science ®Google Scholar
• De Paepe A, Devereux RB, Dietz HC, et al: Revised diagnostic criteria for the Marfan Syndrome. Am J Med Genet 1996; 62(4):417–426
   PubMed Web of Science ®Google Scholar
• Alpert BS: Tall stature. Pediatr Rev 1998;19(9):303–305
   Google Scholar
• Grahame R, Pyeritz RE: The Marfan syndrome:, joint and skin manifestations are prevalent and correlated. Br J Rheumatol 1995;34(2):126–131
   PubMedGoogle Scholar
• Godfrey M: The Marfan syndrome, in Beighton P (ed): McKusick's Heritable Disorders of Connective Tissue, ed St Louis, Mosby-Year Book, 1993, pp 66–68
   Google Scholar
• Sisk HE, Zahka KG, Pyeritz RE: The Marfan syndrome in early childhood: analysis of 15 patients diagnosed at less than 4 years of age. Am J Cardiol 1983;52(3):353–358
   PubMed Web of Science ®Google Scholar
• Geva T, Sanders SR Diogenes MS, et al: Two-dimensional and Doppler echocardiographic and pathologic characteristics of the infantile Marfan syndrome. Am J Cardiol 1990;65(18): 1230–1237
   PubMed Web of Science ®Google Scholar
• Robinson PN, Godfrey M: The molecular genetics of Marfan syndrome and the related microfibrillopathies. J Med Genet 2000;37(l):9–25
   Google Scholar
• Milewicz DM, Pyeritz RE, Crawford ES, et al: Marfan syndrome: defective synthesis, secretion, and extracellular matrix formation of fibrillin by cultured dermal fibroblasts. I Clin Invest 1992;89(1):79–86
   Google Scholar
• Roman MJ, Rosen SE, Kramer-Fox R, et al: Prognostic significance of the pattern of aortic root dilation in the Marfan syndrome. J Am Coll Cardiol 1993;22(5):1470–1476
   PubMed Web of Science ®Google Scholar
• Silverman DI, Cray J, Roman MJ, et al: Family history of severe cardiovascular disease in Marfan syndrome is associated with increased aortic diameter and decreased survival. J Am Coll Cardiol 1995;26(4): 1062–1067
   PubMed Web of Science ®Google Scholar
• Savolainen A, Keto R Hekali P, et al: Aortic distensibility in children with the Marfan syndrome. Am J Cardiol 1992; 70(6):691–693
   Google Scholar
• Hirata K, Triposkiadis F, Sparks E, et al: The Marfan syndrome: abnormal aortic elastic properties. J Am Coll Cardiol 1991; 18(1):57–63; [published erratum in J Am Coll Cardiol 1992; 19(5): 1120–1121]
   PubMed Web of Science ®Google Scholar
• Yin FC, Brin KR Ting CT, et al: Arterial hemodynamic indexes in Marfans syndrome. Circulation 1989;79(4):854–862
   PubMedGoogle Scholar
• Reed CM, Fox ME, Alpert BS: Aortic biomechanical properties in pediatric patients with the Marfan syndrome, and the effect of atenolol. Am J Cardiol 1993;71(7):606–608
   PubMedGoogle Scholar
• Rios AS, Silber EN, Bavishi N, et al: Effect of long term beta-blockade on aortic root compliance in patients with Marfan syndrome. Am Heart J 1999;137(6):1057–1061
   PubMedGoogle Scholar
• Reed CM, Alpert BS: Assessment of ventricular performance after chronic beta-adrenergic blockade in the Marfan syndrome. Am J Cardiol 1992;70(4):541–542
   Google Scholar
• Simpson CF, Boucek RJ, Noble NL: Influence of d-, 1-, and dl-propranolol, and practolol on beta-amino-propionitrile- induced aortic rupture in turkeys. Toxicol Appl Pharmacol 1976;38(1): 169–175
   Google Scholar
• Ose L, McKusick VA: Prophylactic use of propranolol in the Marfan syndrome to prevent aortic dissection. Birth Defects Orig Artie Ser 1977; 13 (3C): 163–169
   PubMedGoogle Scholar
• Shores J, Berger KR, Murphy EA, et al: Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marian's syndrome. N Engl J Med 1994;330(19):1335–1341
   PubMed Web of Science ®Google Scholar
• Salim MA, Alpert BS, Ward JC, et al: Effect of beta-adrenergic blockade on aortic root rate of dilation in the Marfan syndrome. Am J Cardiol 1994;74(6):629–633
   PubMed Web of Science ®Google Scholar
• Salim MA, Alpert BS. Medical management of young patients with the Marfan syndrome. Prog Pediatr Cardiol 1996;5:167–174
   Google Scholar
• Gott VL, Pyeritz RE, Cameron DE, et al: Composite graft repair of Marfan aneurysm of the ascending aorta: results in 100 patients. Ann Thorac Surg 1991;52(1):38–45
   Google Scholar
• Gott VL, Greene PS, Alejo DE, et al: Replacement of the aortic root in patients with Marfan's syndrome. N Engl J Med 1999;340(17): 1307–1313
   PubMed Web of Science ®Google Scholar
• Mitchell JH, Haskell WL, Raven PB: Classification of sports. J Am Coll Cardiol 1994;24(4):864–866
   Google Scholar
• van den Brink RB, Verheul HA, Visser CA, et al: Value of exercise Doppler echocardiography in patients with prosthetic or bioprosthetic cardiac valves. Am J Cardio 1992:69(4): 367–372
   Google Scholar
• Graham TP Jr, Bricker JT, James FW, et al: 26th Bethesda conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task Force 1: congenital heart disease J Am Coll Cardiol 1994;24(4):867–873
   Google Scholar
• Cheitlin MD, Douglas PS, Parmley WW: 26th Bethesda conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task Force 2: acquired valvular heart disease. J Am Coll Cardiol 1994;24(4):874–880
   Google Scholar